UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Circulating Tumor Cells as a Window on Metastasis Biology in Lung Cancer

The American journal of pathology, 2011-03, Vol.178 (3), p.989-996

2011

Volltextzugriff (PDF)

Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

Nature communications, 2023-07, Vol.14 (1), p.4444-4444, Article 4444

2023

Volltextzugriff (PDF)

Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

Nature communications, 2023-08, Vol.14 (1), p.4741-4741, Article 4741

2023

Volltextzugriff (PDF)

A Phase 1 Randomized, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Enteric-Coated Stabilized Sulforaphane (SFX-01) in Male Participants

Advances in therapy, 2024-11

2024

Volltextzugriff (PDF)

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study

Clinical cancer research, 2021-10, Vol.27 (19), p.5213-5224

2021

Volltextzugriff (PDF)

Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement

British journal of cancer, 2020-02, Vol.122 (4), p.473-482

2020

Volltextzugriff (PDF)

The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers

Cancer chemotherapy and pharmacology, 2008-01, Vol.61 (1), p.23-32

2008

Volltextzugriff (PDF)

Abstract PS13-05: A phase 2 study of oral paclitaxel and encequidar (oPac+E) in the treatment of cutnaeous angiosarcoma: The breast angiosarcoma subgroup

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS13-05-PS13-05

2021

Volltextzugriff (PDF)

A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer

The oncologist (Dayton, Ohio), 2023-12, Vol.28 (12), p.e1248-e1258

2023

Volltextzugriff (PDF)

Abstract GS3-10: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.GS3-10-GS3-10

2022

Volltextzugriff (PDF)

Abstract P1-18-10: A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P1-P1-18-10

2022

Volltextzugriff (PDF)

Abstract 4791: OMO-1, a potent, highly selective, orally bioavailable, MET kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against MET pathway-driven tumors, and EGFR TKI combination activity in acquired resistance models

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4791-4791

2018

Volltextzugriff (PDF)

Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System

The Journal of molecular diagnostics : JMD, 2014-05, Vol.16 (3), p.343-349

2014

Volltextzugriff (PDF)

Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data

BMC cancer, 2016-08, Vol.16 (1), p.703-703, Article 703

2016

Volltextzugriff (PDF)

Abstract PO3-04-12: SUMIT-BC: Phase 2 randomized study of fulvestrant with or without the cyclin-dependent kinase 7 inhibitor (CDK7i) samuraciclib in advanced hormone receptor positive (HR+) breast cancer after CDK4/6i

Cancer research (Chicago, Ill.), 2024-05, Vol.84 (9_Supplement), p.PO3-04-12-PO3-04-12

2024

Volltextzugriff (PDF)

Abstract PO3-04-13: SUMIT-ELA: Phase 1b/2 combination of cyclin-dependent kinase 7 inhibitor (CDK7i) samuraciclib and selective estrogen receptor degrader (SERD) elacestrant in advanced hormone receptor positive (HR+) breast cancer after CDK4/6i

Cancer research (Chicago, Ill.), 2024-05, Vol.84 (9_Supplement), p.PO3-04-13-PO3-04-13

2024

Volltextzugriff (PDF)

Effects of third generation aromatase inhibitors on bone health and other safety parameters: Results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women

European journal of cancer (1990), 2007-11, Vol.43 (17), p.2523-2531

2007

Volltextzugriff (PDF)

The Androgen Receptor in Castration-Resistant Prostate Cancer: Still a Clinical Opportunity?

Journal of cancer science & therapy, 2012, Vol.1 (S5)

2012

Volltextzugriff (PDF)

Translational modelling of preclinical cardiovascular findings to patients

Journal of pharmacological and toxicological methods, 2014-11, Vol.70 (3), p.326-327

2014

Volltextzugriff (PDF)

Tissue collection in drug discovery and development research

European journal of cancer supplements, 2007-12, Vol.5 (9), p.33-36

2007

Volltextzugriff (PDF)

Clinical pharmacology profile of an oral selective androgen receptor down-regulator, AZD3514: Implications on the design of ongoing castrate-resistant prostate cancer clinical studies

Cancer Research Frontiers, 2016-09, Vol.2 (3), p.330-351

2016

Volltextzugriff (PDF)

1 – 21 von 21

Suche als RSS-Feed

Aktive Filter

KollektionJournals@Ovid Complete

ThemaAdult

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(19)
Mit Volltextzugriff
(17)

Publikationsform

Artikel
(21)

Sprache

Englisch
(21)

Erscheinungsjahr

n.n

Thema

Science & Technology
(10)
Humans
(9)
Life Sciences & Biomedicine
(9)
Oncology
(7)
Biological And Medical Sciences
(3)
Clinical Trials
(3)
Female
(3)
Male
(3)
Medical Sciences
(3)
Middle Aged
(3)
Tumors
(3)
631/67/1059/153
(2)
692/308/153
(2)
692/4028/67/1347
(2)
Aged
(2)
Biopsy
(2)
Cancer
(2)
Cancer Research
(2)
Hematology, Oncology And Palliative Medicine
(2)
Humanities And Social Sciences
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Circulating Tumor Cells as a Window on Metastasis Biology in Lung Cancer

Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

A Phase 1 Randomized, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Enteric-Coated Stabilized Sulforaphane (SFX-01) in Male Participants

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study

Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement

The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers

Abstract PS13-05: A phase 2 study of oral paclitaxel and encequidar (oPac+E) in the treatment of cutnaeous angiosarcoma: The breast angiosarcoma subgroup

A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer

Abstract GS3-10: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)

Abstract P1-18-10: A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)

Abstract 4791: OMO-1, a potent, highly selective, orally bioavailable, MET kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against MET pathway-driven tumors, and EGFR TKI combination activity in acquired resistance models

Analytical Validation of BRAF Mutation Testing from Circulating Free DNA Using the Amplification Refractory Mutation Testing System

Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data

Abstract PO3-04-12: SUMIT-BC: Phase 2 randomized study of fulvestrant with or without the cyclin-dependent kinase 7 inhibitor (CDK7i) samuraciclib in advanced hormone receptor positive (HR+) breast cancer after CDK4/6i

Abstract PO3-04-13: SUMIT-ELA: Phase 1b/2 combination of cyclin-dependent kinase 7 inhibitor (CDK7i) samuraciclib and selective estrogen receptor degrader (SERD) elacestrant in advanced hormone receptor positive (HR+) breast cancer after CDK4/6i

Effects of third generation aromatase inhibitors on bone health and other safety parameters: Results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women

The Androgen Receptor in Castration-Resistant Prostate Cancer: Still a Clinical Opportunity?

Translational modelling of preclinical cardiovascular findings to patients

Tissue collection in drug discovery and development research

Clinical pharmacology profile of an oral selective androgen receptor down-regulator, AZD3514: Implications on the design of ongoing castrate-resistant prostate cancer clinical studies

Aktive Filter

Suchergebnisse filtern